Epidermolysis bullosa simplex. Photo by James Heilman, MD, via Wikimedia Commons Researchers have developed the first disease-specific clinical tool to assess the severity of epidermolysis bullosa simplex (EBS), according to a study recently published in JAMA Dermatology . EBS is the most common subtype of epidermolysis bullosa. Despite its prevalence, there is no U.S. Food and Drug Administration-approved treatment for EBS, and clinicians have lacked a standardized method for measuring...

Dr. Antoni Ribas, senior author of the study and director of the UCLA Health Jonsson Comprehensive Cancer Center’s Tumour Immunology...

Dr. Jérôme Coulombe When children present with unexplained bumps or masses on their skin, Doppler ultrasound is increasingly becoming the...